Christian L Roth
University of Washington, Dept. of Pediatrics · Seattle Children's Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christian L Roth as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:02 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06299891 · Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic ObesitySeattle Children's Hospital · active not recruiting · Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma · principal investigator
- N/ANCT03109587 · Pilot Study of Probiotics in Pre-diabetic AdolescentsSeattle Children's Hospital · completed · Obesity, Childhood · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Development of Anorexigenic and Glucoregulatory Chimeric PeptidesR01DK135125 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · fiscal years 2023 to 2026 · $677,751 awarded in 2026Same name and institution; not confirmed by an ID
- Phentermine/Topiramate in children, adolescents, and young adults with hypothalamic obesity: a pilot and feasibility studyR01DK135211 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · fiscal years 2023 to 2026 · $342,138 awarded in 2026Same name and institution; not confirmed by an ID
- Efficacy of Novel Melanocortin and Gut-peptide Dual Agonists for Childhood Obesity TreatmentR21HD115119 · NICHD · SEATTLE CHILDREN'S HOSPITAL · fiscal years 2024 · $531,174 awarded in 2024Same name and institution; not confirmed by an ID
- Brain systems and behaviors underlying response to obesity treatment in childrenR01DK098466 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · fiscal years 2014 to 2023 · $656,880 awarded in 2023Same name and institution; not confirmed by an ID
- Glucagon-like peptide-1 agonist effects on energy balance in hypothalamic obesityR01DK104936 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · fiscal years 2015 to 2018 · $296,126 awarded in 2018Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:02 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis.J Clin Endocrinol Metab · 2012146 citationsRCR 4.8
- Androgens before and after weight loss in obese children.J Clin Endocrinol Metab · 2005113 citationsRCR 3.1
- 86 citationsRCR 2.1
- A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity.Diabetes Obes Metab · 202177 citationsRCR 5.6
- Retinol-binding protein 4 and its relation to insulin resistance in obese children before and after weight loss.J Clin Endocrinol Metab · 200875 citationsRCR 2.1
- Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial.Lancet Diabetes Endocrinol · 202473 citationsRCR 11.3
- Appetite-regulating hormone changes in patients with craniopharyngioma.Obesity (Silver Spring) · 201166 citationsRCR 2.2
- Obestatin and ghrelin levels in obese children and adolescents before and after reduction of overweight.Clin Endocrinol (Oxf) · 200856 citationsRCR 1.7
- Ghrelin and obestatin levels in severely obese women before and after weight loss after Roux-en-Y gastric bypass surgery.Obes Surg · 200952 citationsRCR 1.6
- Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist.Int J Obes (Lond) · 202245 citationsRCR 4.0